Evidence map›Paper›PMID 36420104›Full record

ArticleSynthetic communications2022

Design and synthesis of a novel ZB716-d6 as a stable isotopically labeled internal standard.

Shilong Zheng, Jiawang Liu, Borui Kang, Guangdi Wang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Synthetic communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Shilong ZhengRCMI Cancer Research Center and Department of Chemistry, Xavier University of Louisiana, New Orleans, LA, USA.
Jiawang LiuDepartment of Pharmaceutical Science and Medicinal Chemistry Core, University of Tennessee Health Science Center, Memphis, TN, USA.
Borui KangRCMI Cancer Research Center and Department of Chemistry, Xavier University of Louisiana, New Orleans, LA, USA.
Guangdi WangRCMI Cancer Research Center and Department of Chemistry, Xavier University of Louisiana, New Orleans, LA, USA.
Xavier University of Louisiana · USUniversity of Tennessee Health Science Center · US

Funding

Xavier RCMI Renewal Application-Research Infrastructure CoreU54MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI LaKeisha Williams · 2019 to 2026
$41.9M
NIMHD NIH HHS U54 MD007595
6 · The paper itself

Abstract

ZB716 is a synthetic, steroidal, orally active anti-estrogen agent that is under clinical development for the treatment of estrogen receptor (ER)-positive metastatic breast cancer. The stable isotope-labeled ZB716 was required for use as an internal standard in LC-MS/MS assays. Therefore, a novel deuterated ZB716 (ZB716-d6) as an isotopically labeled internal standard was designed and synthesized through a newly developed route, which prepared ZB716-d6 in eight steps from the commercially available deuterium-labeled starting material [

Indexed as

Internal standardoral SERDstable isotopeZB716

Identifiers

PMID36420104
PMCPMC9681137
OpenAlexW4284665090

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.